Bulletin
Investor Alert

Market Pulse Archives

June 21, 2021, 12:53 p.m. EDT

Tarsus to submit application for new eye treatment to FDA in 2022

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Tarsus Pharmaceuticals Inc. (TARS)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Tarsus Pharmaceuticals Inc. /zigman2/quotes/221842319/composite TARS +0.42% said Monday that a Phase 2b/3 clinical trial evaluating an experimental treatment for a type of ocular disease met the study's primary and secondary endpoints. However, the stock was down 15.3% in trading on Monday afternoon. Tarsus is testing the investigational ophthalmic solution in patients with Demodex blepharitis. The company said in a news release that millions of people have been diagnosed with this eye disease, and there are currently no approved treatments in the U.S. Tarsus plans to submit data from this study in a new drug application to the Food and Drug Administration sometime next year. Tarsus shares are down 28.5% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.08% is up 10.9%.

/zigman2/quotes/221842319/composite
US : U.S.: Nasdaq
$ 21.54
+0.09 +0.42%
Volume: 17,295
Sept. 21, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$441.31 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,354.19
-3.54 -0.08%
Volume: 1.91B
Sept. 21, 2021 5:12p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.